We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?
- Authors
Pathak, Atul; Mrabeti, Sanaa
- Abstract
β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β1 vs β2 receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β2 stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of β-blockade in these conditions arises from blockade of the β1 receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of β-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective β-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective β1-adrenoceptor blocker, bisoprolol.
- Subjects
CORONARY disease; MYOCARDIAL ischemia; HEART failure; ANGINA pectoris; MYOCARDIAL infarction
- Publication
Vascular Health & Risk Management, 2021, Vol 17, p337
- ISSN
1176-6344
- Publication type
Article
- DOI
10.2147/VHRM.S285907